SELLAS Life Sciences Group, Inc. (SLS) Income Statement

The company remains pre-revenue, with zero gross profit across all quarters, so growth is not measured by top-line expansion but by the pace of cash consumption. Net losses have increased by roughly 28% year-over-year, suggesting that investment in R&D and SG&A is accelerating without corresponding revenue generation. This pattern implies a reliance on external funding to sustain operations, and investors should monitor the burn rate relative to available capital.

The sequential increase in R&D, particularly the jump from $5.1M in 2026Q1 to $6.3M in 2026Q2, suggests a ramp-up in clinical trial activities, possibly for late-stage programs. SG&A has nearly doubled over the two-year period, which may reflect increased corporate infrastructure and pre-commercialization efforts. However, without revenue, these cost increases directly widen operating losses, and the lack of cost containment raises questions about management's expense discipline relative to the company's cash runway.

The sharp reduction in both R&D and SG&A in early 2025 appears to be a strategic pivot to extend cash runway, possibly by prioritizing certain programs or renegotiating contracts. This inflection led to a temporary stabilization of quarterly losses around $6-7M, but subsequent quarters show a renewed increase in spending, particularly in R&D, suggesting a shift back to investment mode. The lasting impact is a volatile expense profile that complicates forecasting and underscores the company's dependence on capital markets.